TRT and Mortality in Older Men

Author: PubMed
TRT and Mortality in Older Men

This review demonstrates there are benefits to treating older men with TRT to improve sexual function, increase lean muscle mass and strength, improve mood and cognitive function, and reduce frailty and osteoporosis. This article confirms that there is no evidence that TRT is associated with increased risk of prostate cancer or symptomatic benign prostatic hyperplasia.  The author also notes that TRT reduced all-cause mortality. The author mentions that although injections may be associated with decreased cardiovascular risk, the transdermal route may be associated with potentially relatively greater risk because of conversion to dihydrotestosterone (DHT) by the effect of 5-alpha reductase in the skin.

https://pubmed.ncbi.nlm.nih.gov/26482385/

While US testosterone prescriptions have tripled in the last decade with lower trends in Europe, debate continues over the risks, benefits and appropriate use of testosterone replacement therapy (TRT). Several authors blame advertising and the availability of more convenient formulations, whilst others have pointed out that the routine testing of men with erectile dysfunction (ED) (a significant marker of cardiovascular risk) and those with diabetes would inevitably increase the diagnosis of hypogonadism and lead to an increase in totally appropriate prescribing. They commented that this was merely an appropriate correction of previous under-diagnosis and under-treatment in line with evidence based guidelines. It is unlikely that persuasive advertising or convenient formulations could grow a market over such a sustained period if the treatment was not effective. Urologists and primary care physicians are the most frequent initiators of TRT usually for ED. Benefits are clearly established for sexual function, increase in lean muscle mass and strength, mood and cognitive function, with a possible reduction in frailty and osteoporosis. There remains no evidence that TRT is associated with increased risk of prostate cancer or symptomatic benign prostatic hyperplasia, yet the decision to initiate and continue therapy is often decided by urologists. The cardiovascular issues associated with TRT have been clarified by recent studies showing that therapy associated with clear increases in serum testosterone levels to the normal range is associated with reduced all-cause mortality. Studies reporting to show increased risk have been subject to flawed designs with inadequate baseline diagnosis and follow-up testing. Effectively, they have compared non-treated patients with under-treated or non-compliant subjects involving a range of different therapy regimes. Recent evidence suggests long-acting injections may be associated with decreased cardiovascular risk, but the transdermal route may be associated with potentially relatively greater risk because of conversion to dihydrotestosterone by the effect of 5-alpha reductase in skin. The multiple effects of TRT may add up to a considerable benefit to the patient that might be underestimated by the physician primarily concerned with his own specialty. In a response to concerns about the possible risks associated with inappropriate prescribing expressed by Public Citizen, the Food and Drug Administration (FDA) published a complete refutation of all the concerns, only to issue a subsequent bulletin of concern over inappropriate use, whilst confirming the benefits in treating men with established testosterone deficiency. No additional evidence was provided for this apparent change of opinion, but longer term safety data on testosterone products were strongly suggested. In contrast, the European Medicines Agency (EMA), in November 2014, concluded that “there is no consistent evidence of increased cardiovascular risk with testosterone products”. This paper explores the most recent evidence surrounding the benefits and risks associated with TRT.

Get $30 off your first month’s order

Enter your email address now to receive $30 off your first month’s cost, other discounts, and additional information about TRT.

Legal Disclaimer

This website is a repository of publicly available information and is not intended to form a physician-patient relationship with any individual. The content of this website is for informational purposes only. The information presented on this website is not intended to take the place of your personal physician’s advice and is not intended to diagnose, treat, cure, or prevent any disease. Discuss this information with your own physician or healthcare provider to determine what is right for you. All information is intended for your general knowledge only and is not a substitute for medical advice or treatment for specific medical conditions. The information contained herein is presented in summary form only and intended to provide broad consumer understanding and knowledge. The information should not be considered complete and should not be used in place of a visit, phone or telemedicine call, consultation or advice of your physician or other healthcare provider. Only a qualified physician in your state can determine if you qualify for and should undertake treatment.